Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
21 May 1999 to 09 September 1999
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Justification for type of information:
Read across to substance with the same functional groups.
Cross-reference
Reason / purpose for cross-reference:
other: read-across target
Reference
Endpoint:
acute toxicity: oral
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
supporting study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Study conducted on read-across material
Justification for type of information:
Read across to substance with the same functional groups.
Reason / purpose for cross-reference:
read-across source
Key result
Sex:
female
Dose descriptor:
LD50
Effect level:
> 5 000 mg/kg bw
Based on:
test mat.
Key result
Sex:
male
Effect level:
> 2 959 - < 5 000 mg/kg bw
Based on:
test mat.
Key result
Sex:
male/female
Dose descriptor:
LD50
Effect level:
ca. 5 000 mg/kg bw
Based on:
test mat.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1999
Report date:
1999

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Deviations:
not specified
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.1100 (Acute Oral Toxicity)
Deviations:
not specified
Principles of method if other than guideline:
Not relevant
GLP compliance:
yes
Test type:
standard acute method
Limit test:
yes

Test material

1
Reference substance name:
Cycloaliphatic Epoxy Resin ERL-422 1
IUPAC Name:
Cycloaliphatic Epoxy Resin ERL-422 1
Test material form:
liquid: viscous
Details on test material:
- Storage condition of test material: Original container at room temperature
- Physical state: Clear, colourless, viscous liquid

Test animals

Species:
rat
Strain:
other: Crl:CD(SD)IGS BR
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Age at study initiation: Eight to nine weeks old (males) and nine to 10 weeks old (females)
- Weight at study initiation: 264 to 299 g (males) and 200 to 228 g (females)
- Fasting period before study: Food was withheld during the 18- to 20-hour period immediately prior to dosing and returned three to four hours after dosing.
- Housing: Individually in suspended wire-mesh cages.
- Diet: ad libitum
- Water: Reverse osmosis treated municipal water
- Acclimation period: Minimum of seven days prior to initiation of dosing.

ENVIRONMENTAL CONDITIONS
- Temperature: 21.8 - 22.3 °C
- Humidity: 43.3-62.4 %
- Photoperiod (hrs dark / hrs light): 12 hours light/12 hours dark

IN-LIFE DATES: From: May 21, 1999 To: June 11, 1999

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
unchanged (no vehicle)
Details on oral exposure:
MAXIMUM DOSE VOLUME APPLIED: The dose volume was determined by dividing the dose levels of 2959 and 5000 mg/kg, by the specific gravity (1180 mg/mL). Individual doses of the test material were calculated based on body weights obtained just prior to dosing and dose levels of 2.51 and 4.24 mL/kg for the 2959 and 5000 mg/kg groups, respectively.

DOSAGE PREPARATION (if unusual):
A sufficient amount of test material, agitated prior to use, was transferred from the original container to a labelled storage container. A stir bar was added, and the test material was stirred continuously throughout use.

Doses:
2959 and 5000 mg/kg
No. of animals per sex per dose:
20 animals (10 male and 10 female)
Groups of five male and five female were administered either 2959 or 5000 mg/kg dose levels.
Control animals:
not specified
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: The rats were observed at approximately 1, 3 and 4 hours post-dosing on day 0 and once daily thereafter for 14 days. Body weights were obtained and recorded on study days -1, 0 (initiation), 7 and 14 (termination). In addition, decedents were weighed as soon as they were found.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight; other: The major organ systems of the cranial, thoracic and abdominal cavities were examined for all animals.

Results and discussion

Preliminary study:
Not applicable.
Effect levelsopen allclose all
Key result
Sex:
female
Dose descriptor:
LD50
Effect level:
> 5 000 mg/kg bw
Based on:
test mat.
Key result
Sex:
male
Dose descriptor:
LD50
Effect level:
> 2 959 - < 5 000 mg/kg bw
Based on:
test mat.
Key result
Sex:
male/female
Dose descriptor:
LD50
Effect level:
ca. 5 000 mg/kg bw
Based on:
test mat.
Mortality:
Three males and two females died within six days of dosing. Mortality was 0/10 and 5/10 for the 2959 and 5000 mg/kg groups, respectively. Single deaths occurred on days 2, 3, 4, 5 and 6.
Clinical signs:
other: Clinical findings were noted in both dose groups during the first week of the study. Four animals in the 2959 mg/kg group and all animals in the 5000 mg/kg group were noted with various discoloured areas due to discharges/excretions [described as wet and/
Gross pathology:
Three animals (one male and two females) that died were noted with dark red contents in the stomach and/or a distended stomach. Various red and/or yellow matting around the eyes, nose, anogenital and/or urogenital area was noted for these animals that died. There were no other necropsy findings for animals found dead. One male from the 5000 mg/kg group was noted with capsular scarring of the spleen at the scheduled necropsy. There were no other findings for any examined tissues at the scheduled necropsy.

Applicant's summary and conclusion

Interpretation of results:
other: Not classified in accordance with EU Criteria
Conclusions:
The results of this study indicate that the LD50 of the test material was found to be approximately 5000 mg/kg in fasted male and female albino rats when administered once orally via gavage. Based on these results, it was not necessary to classify the test material according to Regulation EC No. 1272/2008 or Directive 67/548/EEC.
Executive summary:

The acute oral toxicity of the test material was investigated in accordance with the standardised guidelines OECD 401 and EPA OPPTS 870.1100, under GLP conditions.

In a study conducted by Kern (1999), the acute oral toxicity of the test material was evaluated in a single-dose study in rats. The test material was administered once orally via gavage to groups of five male and five female fasted albino rats at dose levels of 2959 and 5000 mg/kg. The animals were observed at regular intervals for up to 14 days following administration to ascertain any changes in body weight or clinical behaviour. At termination of the study after 14 days, the animals were necropsied and any changes in the major organs was recorded.

3 males and 2 females in the 5000 mg/kg group died within six days of dosing. Mortality was 0/10 and 5/10 for the 2959 and 5000 mg/kg groups, respectively. Clinical findings were noted in both dose groups during the first week of the study with observations including various discoloured areas due to discharges/excretions, hypoactivity and/or impaired muscle coordination. Animals in the higher dose group were noted with decreased defecation, decreased urination, laboured respiration and/or convulsions. All animals appeared normal by day 6 and throughout the remainder of the study. Three animals that died were noted with gastric abnormalities. There were no other internal gross necropsy findings for animals found dead.

The LD50 of the test material was found to be approximately 5000 mg/kg in fasted male and female albino rats when administered once orally via gavage. Since the median lethal dose estimate was much higher than the test guideline limit, it was not necessary to classify the test material according to Regulation EC No. 1272/2008 or Directive 67/548/EEC.